ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

adagrasib

Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.

Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.

Drug pageAdagrasib: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 28, 202016 company-led studies, 7 open or runningNext primary completion: Feb 16, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb157 open or runningphase 3since Oct 28, 2020Dec 18, 2018Feb 16, 2028phase 2 · NCT07415031
Zai Labits history only10 open or runningphase 1since Jan 13, 2022Jan 13, 2022none ahead

Also a collaborator on its studies: Aadi Bioscience, Novartis and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 1 study since Dec 18, 2018.

  1. Mar 30, 2020Phase 1 study in Neoplasm MetastasisNCT04330664 · 86 enrolled · United States
  2. Oct 28, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04613596 · 626 planned · United States, Argentina, Australia and more
  3. Dec 19, 2020Named adagrasibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, MRTX849
  4. Dec 21, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04685135 · 453 enrolled · United States, Australia, Austria and more
  5. Mar 2, 2021Phase 3 study in Colorectal NeoplasmsNCT04793958 · 461 enrolled · United States, Argentina, Australia and more
  6. Jul 6, 2021Phase 1 study in Neoplasm MetastasisNCT04975256 · 7 enrolled · United States
  7. Dec 1, 2021Phase 1 study in Advanced Solid TumorNCT05178888 · 11 enrolled · United States
  8. Apr 12, 2023Phase 2 study in Neoplasm MetastasisNCT05853575 · 200 enrolled · United States, Brazil, Croatia and more
  9. Apr 12, 2023Phase 1 study in Neoplasm MetastasisNCT05840510 · 6 enrolled · United States
  10. Jun 20, 2023Phase 1 study in Healthy AdultsNCT05924152 · 16 enrolled · United States
  11. Aug 29, 2023Phase 2 study in Biliary Tract NeoplasmsNCT06024174 · 5 enrolled · United States, Australia, Finland and more
  12. Jan 24, 2025Phase 1 study in Healthy VolunteersNCT06801418 · 160 enrolled · United States
  13. Mar 7, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06875310 · 630 planned · United States, Argentina, Australia and more
  14. Feb 11, 2026Phase 2 study in Solid TumorsNCT07415031 · 170 planned · United States, Australia, Belgium and more
  15. Jul 20, 2026Phase 1 study in Healthy ParticipantsNCT07723118 · 10 enrolled · United States

Ahead

  1. Feb 16, 2028Primary completion: phase 2 study in Solid TumorsNCT07415031
  2. Oct 31, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT04613596
  3. Sep 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06875310

TargetBeta

KRAS →read by rule
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 15 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07723118Healthy Participants · United States1CompletedSep 8, 202610
NCT07415031Solid Tumors · United States, Australia, Belgium and more2RecruitingFeb 16, 2028170
NCT06875310Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingSep 7, 2029630
NCT06801418Healthy Volunteers · United States1CompletedJun 19, 2025160
NCT06024174Biliary Tract Neoplasms · United States, Australia, Finland and more2TerminatedMay 13, 20245
NCT05924152Healthy Adults · United States1CompletedAug 9, 202316
NCT05853575Neoplasm Metastasis · United States, Brazil, Croatia and more2Active, not recruitingOct 30, 2026200
NCT05840510Neoplasm Metastasis · United States1TerminatedDec 27, 20246
NCT05178888Advanced Solid Tumor · United States1CompletedJun 15, 202311
NCT04975256Neoplasm Metastasis · United States1TerminatedNov 2, 20227
NCT04793958Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJan 16, 2026461
NCT04685135Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3Active, not recruitingDec 30, 2023453
NCT04613596Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingOct 31, 2028626
NCT04330664Neoplasm Metastasis · United States1CompletedJul 29, 202286
NCT03785249Neoplasm Metastasis · United States, Puerto Rico2Active, not recruitingJun 23, 2026731

How it is read

Names in the registry

  • “Adagrasib”, 12 entries
  • “MRTX849”, 7 entries
  • “Eltrombopag + adagrasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.